Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of issues, including mild anxiety to insomnia, Shalini Ramachandran and Betsy McKay of The Wall Street Journal reports. Benzodiazepines became some of the most commonly prescribed psychiatric medications in America, but as concerns increase about potential adverse effects of the drug, some patients who try to quite are experiencing an intense hangover and are unable to drop the drug. Companies involved in Xanax include Pfizer (PFE) and Viatris (VTRS).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Biotech Alert: Searches spiking for these stocks today
- Arvinas price target lowered to $12 from $48 at Morgan Stanley
- ViiV announces new study data showing zero HIV cases with Apretude
- ViiV Healthcare announces data from EMBRACE Phase IIb study
- Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint in Phase 3 trial